JAZZ PHARMACEUTICALS SOBRE LOS RIESGOS E INCERTIDUMBRES CON LURBINECTEDIN ( ZEPZELCA ) ... : PREVEMOS QUE LURBINECTEDIN ( ZEPZELCA ) COMPITA CON PRODUCTOS GENÉRICOS EN EL FUTURO .
Results from a randomized, placebo-controlled trial in patients with a history of venous thromboembolic events suggest a benefit for maintenance therapy with rivaroxaban, an investigational oral selective Factor Xa inhibitor. ...